eprintid: 10051921
rev_number: 29
eprint_status: archive
userid: 608
dir: disk0/10/05/19/21
datestamp: 2018-07-12 10:40:23
lastmod: 2021-09-17 22:09:23
status_changed: 2019-06-24 12:49:23
type: article
metadata_visibility: show
creators_name: Hansson, O
creators_name: Seibyl, J
creators_name: Stomrud, E
creators_name: Zetterberg, H
creators_name: Trojanowski, JQ
creators_name: Bittner, T
creators_name: Lifke, V
creators_name: Corradini, V
creators_name: Eichenlaub, U
creators_name: Batrla, R
creators_name: Buck, K
creators_name: Zink, K
creators_name: Rabe, C
creators_name: Blennow, K
creators_name: Shaw, LM
creators_name: Swedish BioFINDER study group, .
creators_name: Alzheimer's Disease Neuroimaging Initiative, .
title: CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Amyloid PET concordance, Amyloid-β (1–42), Biomarker validation, CSF biomarkers, Clinical progression, Cutoffs, Phosphorylated tau (pTau), Total tau (tTau)
note: Copyright © 2018 The Authors. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
abstract: INTRODUCTION: We studied whether fully automated Elecsys cerebrospinal fluid (CSF) immunoassay results were concordant with positron emission tomography (PET) and predicted clinical progression, even with cutoffs established in an independent cohort. METHODS: Cutoffs for Elecsys amyloid-β1-42 (Aβ), total tau/Aβ(1-42), and phosphorylated tau/Aβ(1-42) were defined against [18F]flutemetamol PET in Swedish BioFINDER (n = 277) and validated against [18F]florbetapir PET in Alzheimer's Disease Neuroimaging Initiative (n = 646). Clinical progression in patients with mild cognitive impairment (n = 619) was studied. RESULTS: CSF total tau/Aβ(1-42) and phosphorylated tau/Aβ(1-42) ratios were highly concordant with PET classification in BioFINDER (overall percent agreement: 90%; area under the curve: 94%). The CSF biomarker statuses established by predefined cutoffs were highly concordant with PET classification in Alzheimer's Disease Neuroimaging Initiative (overall percent agreement: 89%-90%; area under the curves: 96%) and predicted greater 2-year clinical decline in patients with mild cognitive impairment. Strikingly, tau/Aβ ratios were as accurate as semiquantitative PET image assessment in predicting visual read-based outcomes. DISCUSSION: Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis.
date: 2018-11
date_type: published
official_url: https://doi.org/10.1016/j.jalz.2018.01.010
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1541282
doi: 10.1016/j.jalz.2018.01.010
pii: S1552-5260(18)30029-3
lyricists_name: Zetterberg, Henrik
lyricists_id: HZETT94
actors_name: Cuccu, Clara
actors_id: CCCUC40
actors_role: owner
full_text_status: public
publication: Alzheimer's & Dementia
volume: 14
number: 11
pagerange: 1470-1481
event_location: United States
issn: 1552-5279
citation:        Hansson, O;    Seibyl, J;    Stomrud, E;    Zetterberg, H;    Trojanowski, JQ;    Bittner, T;    Lifke, V;                                         ... Alzheimer's Disease Neuroimaging Initiative, .; + view all <#>        Hansson, O;  Seibyl, J;  Stomrud, E;  Zetterberg, H;  Trojanowski, JQ;  Bittner, T;  Lifke, V;  Corradini, V;  Eichenlaub, U;  Batrla, R;  Buck, K;  Zink, K;  Rabe, C;  Blennow, K;  Shaw, LM;  Swedish BioFINDER study group, .;  Alzheimer's Disease Neuroimaging Initiative, .;   - view fewer <#>    (2018)    CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.                   Alzheimer's & Dementia , 14  (11)   pp. 1470-1481.    10.1016/j.jalz.2018.01.010 <https://doi.org/10.1016/j.jalz.2018.01.010>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10051921/14/Zetterberg%20VoR%201-s2.0-S1552526018300293-main.pdf
document_url: https://discovery.ucl.ac.uk/id/eprint/10051921/8/1-s2.0-S1552526018300293-mmc1.pdf